HLS Therapeutics Inc. (TSE:HLS - Get Free Report) shares traded up 1.8% on Monday . The stock traded as high as C$4.99 and last traded at C$4.99. 10,000 shares changed hands during mid-day trading, a decline of 28% from the average session volume of 13,795 shares. The stock had previously closed at C$4.90.
Wall Street Analysts Forecast Growth
Separately, Stifel Nicolaus increased their price target on HLS Therapeutics from C$3.50 to C$4.00 and gave the company a "hold" rating in a report on Wednesday, March 26th.
Get Our Latest Stock Report on HLS Therapeutics
HLS Therapeutics Stock Up 1.8%
The stock has a market cap of C$111.02 million, a P/E ratio of -5.00 and a beta of 1.07. The company has a current ratio of 1.56, a quick ratio of 1.01 and a debt-to-equity ratio of 86.50. The firm's fifty day moving average is C$4.58 and its 200 day moving average is C$4.23.
HLS Therapeutics Company Profile
(
Get Free Report)
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider HLS Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HLS Therapeutics wasn't on the list.
While HLS Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
